Singular Research Director’s Letter : January 2018
Out of the Box Hot!
As the adage goes, as goes January as will be the year. Thus, we remain encouraged, hoping earnings can continue to lift already lofty valuations. Indeed, aided by lowered corporate tax rates and lessened regulatory burdens, we have much too support encouraged animal spirits. Still, we suggest selectivity and valuation vigilance as the FED is looking to renormalize the rate environment with the hint of perhaps, several hikes in 2018, suggesting a possible push-pull between higher rates vs. higher earnings.
Meanwhile, small caps continue to lag as investors still favor large cap and accompanying ETF’s extending last year’s leadership forward into 2018 thus far.
For the top performing companies in January on the Singular Research coverage list, a common theme was biotech, led by HBIO, ANIK & IGXT. Harvard Bioscience (HBIO) announced a major acquisition that should lift growth prospects and margins while shedding a low margin, underperforming division. Whereas Anika Pharmaceuticals, lacking an apparent fundamental catalyst, seems to have benefited from a rebound in the Biotech sector spurred by investor allocation to ETF’s. Transcat, (TRNS), got a nice boost from beating estimates from the 2 analysts (including Singular) that follow it.
The worst performing stock on the Singular coverage list during January was by our wrongheaded short call on New York Times, (NYT), which continues to delight with its digit revenue growth results spurred by a long-lived Trump bump. Clear One (CLRO) endured profit taking reaction from a 25% up move in December. It remains an attractive long-term value still trading around book value. Arlington Asset Investment Corp. (AI), surprised the street with better than forecast results and rebounded from an oversold condition that took it below NAV to a 5 year low.
We continue to work on new ideas and plan to launch coverage in the coming weeks on one or several new names. At Singular Research, we continue to seek out investment ideas that have minimal to no Wall Street coverage. We thank our clients for your support of independent equity research.